Concentration-guided dose reduction versus standard dosing in tocilizumab-treated rheumatoid arthritis patients: a randomised, multicenter, non-inferiority trial (TODORA) - Use of TOcilizumab Drug levels to Optimize treatment in RA (TODORA)

Reade0 个研究点目标入组 98 人开始时间: 2019年7月24日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•-Rheumatoid arthritis according to the ACR 1987 or 2010 criteria;
•-Current use of subcutaneous tocilizumab 162 mg weekly, for at least the last 6 months;
•-The treating rheumatologist is convinced of the benefit of tocilizumab continuation;
•-No changes in the treatment with glucocorticoids and DMARDs such as methotrexate in the past three months;
•-Written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 85
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 13

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•-A scheduled surgery in the next 12 months or other pre-planned reasons for treatment discontinuation.

发起方

Reade